Dual Antibody Combo (Tec + Tal) Shows Hope for Hard-to-Treat Myeloma | Saad Usmani, MD

Hello.

My name is Saad Usmani and the chief of the myeloma service at Memorial Sloan-Kettering Cancer Center in New York.

I am presenting the updated results of the Redirectt-1 study, which is the first dedicated trial for true extramedullary multiple myeloma patients.

And it combines teclistamab, which is a BCMA directed bispecific with talquetamab, which is a GPRC5D targeting bispecific.

Individually, each of these bispecific have shown that they have activity in extramedullary disease myeloma patients.

But the median progression free survival may be only about five months or so.

So in this combination of giving both the bispecific simply doing dual targeting 90 patients were treated both with organ extramedullary disease as well as soft tissue or lymph node extramedullary disease.

One key feature of this, study was that we incorporated imaging as part of response criteria using the dual five point score.

The response rates were almost 80%.

And then to our pleasant surprise, the median progression free survival is 15 months, which is quite remarkable for this EMD patient population.

And we also had patients who had prior Car-T cell therapy, as well as some bispecific exposure, in this population.

So these looked like very promising results.

And we are hoping that this can become, potentially a standard of care treatment for our EMD patients.

If our videos have helped you in any way and you're able to, please consider making a donation to help us continue this important work.

Your gift will go three times as far.

When we reached $500,000 by the end of the year,

every contribution, big or small, makes a difference,

and we're deeply grateful for your support.